Antinociceptive properties of physalins from Physalis angulata.
Pain is the most common reason a patient sees a physician. Nevertheless, the use of typical painkillers is not completely effective in controlling all pain syndromes; therefore further attempts have been made to develop improved analgesic drugs. The present study was undertaken to evaluate the antinociceptive properties of physalins B (1), D (2), F (3), and G (4) isolated from Physalis angulata in inflammatory and centrally mediated pain tests in mice. Systemic pretreatment with 1-4 produced dose-related antinociceptive effects on the writhing and formalin tests, traditional screening tools for the assessment of analgesic drugs. On the other hand, only 3 inhibited inflammatory parameters such as hyperalgesia, edema, and local production of TNF-α following induction with complete Freund's adjuvant. Treatment with 1, 3, and 4 produced an antinociceptive effect on the tail flick test, suggesting a centrally mediated antinociception. Reinforcing this idea, 2-4 enhanced the mice latency reaction time during the hot plate test. Mice treated with physalins did not demonstrate motor performance alterations. These results suggest that 1-4 present antinociceptive properties associated with central, but not anti-inflammatory, events and indicate a new pharmacological property of physalins.
Faculdade de Farmácia, Universidade Federal da Bahia , CEP 40170-290, Salvador, BA, Brazil.
Milena da Silva
Mda S
Lima
Afrânio Ferreira
AF
Evangelista
Gisele Graça Leite Dos
GG
Santos
Ivone Maria
IM
Ribeiro
Therezinha Coelho Barbosa
TC
Tomassini
Milena Botelho
MB
Pereira Soares
Cristiane Flora
CF
Villarreal
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D004487:Edema / Q000188:drug therapy; D005620:Freund's Adjuvant; D006930:Hyperalgesia / Q000188:drug therapy; D008297:Male; D051379:Mice; D015394:Molecular Structure; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D032321:Physalis / Q000737:chemistry*; D012632:Secosteroids / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D012632:Secosteroids; D014409:Tumor Necrosis Factor-alpha; C441429:physalin D; C569084:physalin G; C033270:physalin B; C075425:physalin F; D005620:Freund's Adjuvant